Balchem completed the acquisition of Kappa Bioscience for $338m.

Balchem, a global specialty ingredients company, completed the acquisition of Kappa Bioscience, a science-based manufacturer of specialty vitamin K2 for the human nutrition industry, for $338m. "This acquisition accelerates our strategy to expand our portfolio of science-based specialty nutrients with leading positions in growing markets. Vitamin K2 fits squarely with our strategic focus and our vision of ‘making the world a healthier place’. Kappa is the leader within its space and the only company offering a patented, 99.7% all-trans vitamin K2 as MK-7, identical to the bioactive vitamin K2 molecule found in nature. We believe the combining of our two companies will strengthen our scientific and technical expertise, geographic reach, and marketplace leadership while ultimately leading to accelerated growth for both companies’ portfolios," Ted Harris, Balchem Chairman, CEO and President.